Brokerages Set Lyell Immunopharma, Inc. (NASDAQ:LYEL) Target Price at $43.00

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $43.00.

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. Citizens Jmp reissued a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research report on Monday, June 15th. Finally, Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th.

Get Lyell Immunopharma alerts:

Read Our Latest Stock Analysis on LYEL

Institutional Trading of Lyell Immunopharma

A number of hedge funds have recently made changes to their positions in LYEL. AQR Capital Management LLC grew its position in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma during the second quarter worth approximately $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma during the second quarter worth approximately $159,000. BBR Partners LLC bought a new position in Lyell Immunopharma during the fourth quarter worth $210,000. Finally, Walleye Capital LLC bought a new position in Lyell Immunopharma during the second quarter worth $258,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $14.05 on Wednesday. Lyell Immunopharma has a one year low of $8.87 and a one year high of $45.00. The company’s 50 day moving average price is $16.73 and its 200 day moving average price is $22.22. The firm has a market capitalization of $327.79 million, a price-to-earnings ratio of -1.02 and a beta of -0.09.

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting the consensus estimate of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Sell-side analysts forecast that Lyell Immunopharma will post -7.87 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

Featured Stories

• Five stocks we like better than Lyell Immunopharma
• NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
• Amazon Could Be About to Reap the Rewards of a Software Spending Boom
• Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
• AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.